Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scottish Funding No For Two Orphans As SMC Tries To Catch Up After COVID-19 Backlog

Executive Summary

Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.

You may also be interested in...



Scottish HTA Nod For Keytruda In Endometrial Carcinoma Marks UK First

Scotland has approved reimbursement for MSD’s Keytruda in combination with Eisai’s Lenvima for endometrial carcinoma. Meanwhile, a recommendation in England has been delayed.

Scotland's HTA Body Says Fast-Track Yes To UCB’s Bimzelx

The Scottish health technology appraisal body also OKd Janssen's Ponvory and new indications for AstraZeneca’s Tagrisso, Roche’s Tecentriq and MSD’s Keytruda. It also said it could not make recommendations on a number of drugs because manufacturers had not made a submission to the SMC.

German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel